354 related articles for article (PubMed ID: 28694084)
1. Olanzapine Reduces Chemotherapy-induced Nausea and Vomiting Compared With Aprepitant in Myeloma Patients Receiving High-dose Melphalan Before Stem Cell Transplantation: A Retrospective Study.
Trifilio S; Welles C; Seeger K; Mehta S; Fishman M; McGowan K; Strejcek K; Eiten E; Pirotte C; Lucier E; DeFrates S; Mehta J
Clin Lymphoma Myeloma Leuk; 2017 Sep; 17(9):584-589. PubMed ID: 28694084
[TBL] [Abstract][Full Text] [Related]
2. Randomized, Placebo-Controlled, Phase III Trial of Fosaprepitant, Ondansetron, Dexamethasone (FOND) Versus FOND Plus Olanzapine (FOND-O) for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients with Hematologic Malignancies Receiving Highly Emetogenic Chemotherapy and Hematopoietic Cell Transplantation Regimens: The FOND-O Trial.
Clemmons AB; Orr J; Andrick B; Gandhi A; Sportes C; DeRemer D
Biol Blood Marrow Transplant; 2018 Oct; 24(10):2065-2071. PubMed ID: 29906570
[TBL] [Abstract][Full Text] [Related]
3. Multiple-day administration of fosaprepitant combined with tropisetron and olanzapine improves the prevention of nausea and vomiting in patients receiving chemotherapy prior to autologous hematopoietic stem cell transplant: a retrospective study.
Ye P; Pei R; Wang T; Cao J; Zhang P; Chen D; Liu X; Du X; Li S; Tang S; Hu Y; Jiang L; Lu Y
Ann Hematol; 2022 Aug; 101(8):1835-1841. PubMed ID: 35668198
[TBL] [Abstract][Full Text] [Related]
4. Prevention of chemotherapy-induced nausea and vomiting after high-dose melphalan and stem cell transplantation: review of the evidence and suggestions.
Tendas A; Marchesi F; Mengarelli A; Annibali O; Tomarchio V; Saltarelli D; Chierichini A; Di Venanzio M; Sollazzo F; Piedimonte M; Cupelli L; Bruno A; De Angelis G; Delbono L; Niscola P; Perrotti AP; de Fabritiis P; Arcese W;
Support Care Cancer; 2019 Mar; 27(3):793-803. PubMed ID: 30564934
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of aprepitant in preventing nausea and vomiting due to high-dose melphalan-based conditioning for allogeneic hematopoietic stem cell transplantation.
Sakurai M; Mori T; Kato J; Koda Y; Kikuchi T; Kohashi S; Saburi M; Toyama T; Aisa Y; Nakazato T; Beppu N; Tsuda S; Shigematsu N; Okamoto S
Int J Hematol; 2014 Apr; 99(4):457-62. PubMed ID: 24619827
[TBL] [Abstract][Full Text] [Related]
6. Aprepitant for the control of delayed nausea and vomiting associated with the use of high-dose melphalan for autologous peripheral blood stem cell transplants in patients with multiple myeloma: a phase II study.
Bechtel T; McBride A; Crawford B; Bullington S; Hofmeister CC; Benson DM; Jaglowski S; Penza S; Andritsos LA; Devine SM
Support Care Cancer; 2014 Nov; 22(11):2911-6. PubMed ID: 24838259
[TBL] [Abstract][Full Text] [Related]
7. Palonosetron, aprepitant, and dexamethasone for prevention of nausea and vomiting after high-dose melphalan in autologous transplantation for multiple myeloma: A phase II study.
Isoda A; Saito R; Komatsu F; Negishi Y; Oosawa N; Ishikawa T; Miyazawa Y; Matsumoto M; Sawamura M; Manaka A
Int J Hematol; 2017 Apr; 105(4):478-484. PubMed ID: 27873176
[TBL] [Abstract][Full Text] [Related]
8. Aprepitant, granisetron, and dexamethasone for prevention of chemotherapy-induced nausea and vomiting after high-dose melphalan in autologous transplantation for multiple myeloma: results of a randomized, placebo-controlled phase III trial.
Schmitt T; Goldschmidt H; Neben K; Freiberger A; Hüsing J; Gronkowski M; Thalheimer M; Pelzl le H; Mikus G; Burhenne J; Ho AD; Egerer G
J Clin Oncol; 2014 Oct; 32(30):3413-20. PubMed ID: 25225424
[TBL] [Abstract][Full Text] [Related]
9. Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting.
Navari RM; Qin R; Ruddy KJ; Liu H; Powell SF; Bajaj M; Dietrich L; Biggs D; Lafky JM; Loprinzi CL
N Engl J Med; 2016 Jul; 375(2):134-42. PubMed ID: 27410922
[TBL] [Abstract][Full Text] [Related]
10. Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial.
Navari RM; Gray SE; Kerr AC
J Support Oncol; 2011; 9(5):188-95. PubMed ID: 22024310
[TBL] [Abstract][Full Text] [Related]
11. Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting--two new agents.
Navari RM
J Support Oncol; 2003; 1(2):89-103. PubMed ID: 15352652
[TBL] [Abstract][Full Text] [Related]
12. Randomized, double-blind, placebo-controlled study of aprepitant versus two dosages of olanzapine with ondansetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving high-emetogenic chemotherapy.
Ithimakin S; Theeratrakul P; Laocharoenkiat A; Nimmannit A; Akewanlop C; Soparattanapaisarn N; Techawattanawanna S; Korphaisarn K; Danchaivijitr P
Support Care Cancer; 2020 Nov; 28(11):5335-5342. PubMed ID: 32128615
[TBL] [Abstract][Full Text] [Related]
13. Fosaprepitant for the prevention of nausea and vomiting in patients receiving BEAM or high-dose melphalan before autologous hematopoietic stem cell transplant.
Clark SM; Clemmons AB; Schaack L; Garren J; DeRemer DL; Kota VK
J Oncol Pharm Pract; 2016 Jun; 22(3):416-22. PubMed ID: 25956421
[TBL] [Abstract][Full Text] [Related]
14. Olanzapine (5 mg) plus standard triple antiemetic therapy for the prevention of multiple-day cisplatin hemotherapy-induced nausea and vomiting: a prospective randomized controlled study.
Gao J; Zhao J; Jiang C; Chen F; Zhao L; Jiang Y; Li H; Wang W; Wu Y; Jin Y; Da L; Liu G; Zhang Y; Li H; Zhang Z; Jin G; Li Q
Support Care Cancer; 2022 Jul; 30(7):6225-6232. PubMed ID: 35449368
[TBL] [Abstract][Full Text] [Related]
15. The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy.
Navari RM; Nagy CK; Gray SE
Support Care Cancer; 2013 Jun; 21(6):1655-63. PubMed ID: 23314603
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of palonosetron, fosaprepitant, and olanzapine as antiemetic prophylaxis for fludarabine and melphalan-based conditioning regimens prior to allogeneic hematopoietic stem cell transplants.
Karpen R; Sen J; Wall S; Musson S; Tossey J
Leuk Res; 2024 Jan; 136():107431. PubMed ID: 38043326
[TBL] [Abstract][Full Text] [Related]
17. Addition of Aprepitant (Emend®) to Standard Antiemetic Regimen Continued for 7 Days after Chemotherapy for Stem Cell Transplantation Provides Significant Reduction of Vomiting.
Svanberg A; Birgegård G
Oncology; 2015; 89(1):31-6. PubMed ID: 25659986
[TBL] [Abstract][Full Text] [Related]
18. The oral NK(1) antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: Pooled data from 2 randomised, double-blind, placebo controlled trials.
Warr DG; Grunberg SM; Gralla RJ; Hesketh PJ; Roila F; Wit Rd; Carides AD; Taylor A; Evans JK; Horgan KJ
Eur J Cancer; 2005 Jun; 41(9):1278-85. PubMed ID: 15939263
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of olanzapine in patients who fail therapy with aprepitant while receiving highly emetogenic chemotherapy.
Mehra N; Ganesan P; Ganesan TS; Veeriah S; Boopathy A; Radhakrishnan V; Dhanushkodi M; Rajaraman S; Ganesharajah S; Sagar TG
Med Oncol; 2017 Dec; 35(1):12. PubMed ID: 29248965
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of olanzapine combined with aprepitant, palonosetron, and dexamethasone for preventing nausea and vomiting induced by cisplatin-based chemotherapy in gynecological cancer: KCOG-G1301 phase II trial.
Abe M; Hirashima Y; Kasamatsu Y; Kado N; Komeda S; Kuji S; Tanaka A; Takahashi N; Takekuma M; Hihara H; Ichikawa Y; Itonaga Y; Hirakawa T; Nasu K; Miyagi K; Murakami J; Ito K
Support Care Cancer; 2016 Feb; 24(2):675-682. PubMed ID: 26130365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]